ArticleFrontiers in public health2023

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.

Xueyan Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.